Fin Cascade

Prices as of 9 Oct 2026 close · Not investment advice

Indogulf Cropsciences Limited

NSE: IGCLPesticides & Agrochemicals

Share price

₹55.09

-0.94% close of 9 Oct 2026

Market cap ₹347 CrP/E 9.0

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

60

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹347 Cr

P/E ratio

9.0

P/B ratio

0.8

ROCE

12.2%

ROE

10.9%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹110.2552-week low ₹53.40

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 11.8% a year against a sector median of 10.2% — 1.6 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.4 times its growth rate, on earnings growth of 21%.

Profit growthPrice per ₹1 profitPer 1% growth
Indogulf Cropsciences Limited — this one21%/yr9.0×₹0.43
PI Industries Limited-1%/yr29.4×—
Sumitomo Chemical India Limited2%/yr36.4×₹18.2
Bayer Cropscience Limited1%/yr21.4×₹21.4
Sharda Cropchem Limited26%/yr10.4×₹0.40
Rallis India Limited30%/yr17.6×₹0.59

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pesticides & Agrochemicals), it ranks 14 of 23 on returns, 10 of 23 on growth, 16 of 23 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 12.2% on capital, ahead of 39% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹67 crore of cash before any plant spend, funded from lenders and shareholders. And the profit is not backed by cash: it reported a profit over 6 years and consumed cash from the business. Its cash comes back more slowly than it used to: it went from being waiting 86 days for its cash to waiting 158 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 10 checks clear · 90%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 12 Aug 2026 · Consolidated · Unaudited

Revenue

₹169 Cr

Revenue vs last year

-10.8%

Revenue vs last quarter

+11.6%

Net profit

₹2 Cr

Profit vs last year

-39.6%

Profit vs last quarter

-79.9%

Net margin

1.4%

EPS

₹0.38

Earnings call transcript · 18 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹347 Cr
Prev close
₹55.09
52w High
₹111
52w Low
₹49.5
Enterprise value
₹518 Cr
Beta
1.2
Price CAGR 1y
-43.0%
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
4.9%
PEG ratio
0.4
P/E ratio
9.0
P/B ratio
0.8
EV / EBITDA
7.0
Industry P/E
20.1
ROCE
12.2%
ROCE 5y average
13.2%
ROE
10.9%
Debt / Equity
0.4
Interest coverage
4.1
Dividend yield
0.0%
ROE 3y average
12.0%
ROE last year
11.0%

Annual P&L

Annual revenue
₹705 Cr
Annual profit
₹40 Cr
Operating margin
10.0%
Net profit margin
5.7%
EBITDA margin
10.5%
Sales growth 3y
8.6%
Sales growth 5y
9.7%
Profit growth 3y
21.0%
Profit growth 5y
12.0%
EPS
₹6.3
Sales growth TTM
6.0%
Profit growth TTM
14.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹169 Cr
Profit latest quarter
₹2 Cr
YoY quarterly sales growth
-11.0%
YoY quarterly profit growth
-37.7%
OPM latest quarter
5.7%

Balance Sheet

Book Value
₹72.9
Face Value
₹10.0
Total debt
₹183 Cr
Total cash
₹12 Cr
Borrowings
₹183 Cr
Reserves / Equity
6.3

Cash Flow

Operating cash flow
-₹41 Cr
Free cash flow
-₹69 Cr
FCF yield
-24.8%
Net cash flow
₹3 Cr

Shareholding

Promoter holding
69.0%
FII holding
0.2%
DII holding
4.3%
Public holding
26.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
UPL495.0021.141,7731.21-73.092.610,181.010.510.1
P I Industries2,210.0031.033,5300.68244.2-39.01,702.3-10.415.0
Sumitomo Chemi.421.9536.921,0610.31216.59.31,054.10.623.5
Bayer Crop Sci.3,491.5021.415,6924.30321.615.41,835.0-4.229.1
Sharda Cropchem742.0510.76,6952.0288.0-38.31,073.89.030.3
Dhanuka Agritech891.8014.83,9760.2236.3-34.6461.9-12.623.8
Rallis India200.0317.03,8901.50125.030.01,022.06.814.1
Indogulf Cropsci57.759.53650.002.4-37.0168.6-11.012.2
Median316.2021.11,6520.1724.616.8383.7-2.315.4

Competes with: Bayer Cropscience Limited, Dhanuka Agritech Limited, NACL Industries Limited, PI Industries Limited, Rallis India Limited, Sharda Cropchem Limited, Sumitomo Chemical India Limited, UPL Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemMar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales13913223399126189248116151169
Expenses11912620589105179216104130159
Material Cost13716815883102147
Change in Inventories-66-379.82-17-28-34
Purchases of Stock-in-Trade2.51167.557.36169.00
Employee Cost121315141614
Other Expenses201927172523
Operating Profit205.962710219.933212209.55
OPM %154.511210175.241310145.67
Other Income3.431.701.130.631.950.942.312.701.620.86
Exceptional items (within Other Income)0.010.010.360.16-0.38-0.03
Interest3.283.163.184.044.153.794.594.314.384.51
Depreciation2.582.462.642.043.462.432.622.723.682.78
Profit before tax182.04234.61154.65277.38143.12
Tax %28342721351724481723
Net Profit131.35173.669.803.87213.86122.41
EPS in Rs5.500.283.420.752.010.793.270.611.840.38
Diluted EPS in Rs2.100.801.730.772.300.38

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales443486550552590705684
Expenses404442501493526631610
Material Cost455511
Change in Inventories-53-72
Purchases of Stock-in-Trade1247
Employee Cost4657
Other Expenses6587
Operating Profit39454959647474
OPM %99911111011
Other Income243-0587
Exceptional items (within Other Income)1.350.15
Interest561213151718
Depreciation681010111112
Profit before tax30363036455352
Tax %262626222925
Net Profit22262228314039
EPS in Rs9.48119.53126.456.336.10
Diluted EPS in Rs7.026.72
Dividend Payout %000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
10%
3 years
9%
TTM
6%

Compounded profit growth

10 years
—
5 years
12%
3 years
21%
TTM
14%

Stock price CAGR

10 years
—
5 years
—
3 years
—
1 year
-43%

Return on equity

10 years
—
5 years
13%
3 years
12%
Last year
11%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424244963
Reserves130157180208226396
Borrowings79102195159227183
Other Liabilities178139120154188181
Total Liabilities411421519544690823
Fixed Assets515369484749
CWIP699235876
Investments3000012
Other Assets351359440474585687
Total Assets411421519544688823

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity20-7-5753-15-41
Cash from Investing Activity-10-10-19-5-40-37
Cash from Financing Activity-91675-496180
Net Cash Flow1-1-1-173
Free Cash Flow10-19-7747-55-69

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days97115117146138125
Inventory Days205167201195260258
Days Payable1381117910912996
Cash Conversion Cycle164171239232268286
Working Capital Days628691111114158
ROCE %1612131312

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters9769696969
FIIs00.410.210.240.23
DIIs06.234.394.364.30
Public3.1424262626
No. of Shareholders2824,79824,86723,86723,768

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -49.4% (₹108.80 → ₹55.09)Brick size ₹3.40 (fixed)Bricks 32
₹60.00₹80.00₹100₹55.09Nov '25Feb '26May '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹55.09 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

exports as % of revenue

13.00pct

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

171inr_cr

2026-03-31

order book, Rs crore

4.00inr_cr

2025-12-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

R&D as % of revenue

0.23pct

2026-03-31

News

News and filings about Indogulf Cropsciences Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Uses as raw material

  • 2-chloro-5-chloromethylthiazole
  • 3-methyl-4-nitroimino-perhydro-1,3,5-oxadiazine
  • MCPA technical 95%
  • agrochemical raw materials, components and active ingredients
  • bifenthrin
  • bifenthrin alcohol
  • cloquintocet safener
  • fenobucarb 95% technical
  • lambdachloride
  • paraquat dichloride technical
  • tetrahydrofuran

Depends on the price of

  • Crude Oil Brent

Buys from

Sells to

  • International partners in 34+ countries (Mexico, Brazil, Spain, Taiwan, Sri Lanka, Venezuela) · crop protection products, plant nutrients and biologicals; 143 international partners, Two…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Chemicals
Industry
Pesticides & Agrochemicals
Classification
Chemicals › Pesticides & Agrochemicals
ISIN
INE05J901018

Plants

  • Barwasni Manufacturing Facility
  • Nathupur-I Manufacturing Facility
  • Nathupur-II Technical Plant
  • Samba Manufacturing Facility

News impact

Big market events that reach Indogulf Cropsciences Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.